Venetoclax use in Patient with Ataxia Telangiectasia and Early-T-Cell Precursor Acute Lymphoblastic LeukemiaShaikha Alqahtani1, Ramya Ramakrishnan1, Shuyu E2 , Sa A. Wang2, Cesar Nunez1, David McCall1, Miriam B., Garcia1, Michael E. Roth1, Branko Cuglievan1, Amber Gibson1Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Hematopathology, Division of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

UNICENTRIC CASTLEMAN DISEASE AND MICROCYTIC ANEMIA: A CHALLENGING DIAGNOSISAuthors: Kylie Holden1, Olayinka Okeleji2 Miriam B. Garcia2, Mary Austin1, James You3 and David McCall21 Department of Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth Houston) and Children’s Memorial Hermann Hospital, Houston, TX2 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX3 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Relapsed or refractive pediatric B-Acute Lymphoblastic Leukemia (B-ALL) patients have high rates of toxicities and relapse, and novel therapy is needed. We present a case of a 5-year-old male with high-risk B-ALL that was refractive to several re-induction regimens. He was put into MRD-negative remission after re-induction with chemotherapy plus overlapping rituximab, inotuzumab ozogamicin and blinatumomab, termed Mini-Hyper-CVD plus CRIB. This was well tolerated, and he received his transplant and engrafted with no significant infections, toxicities, or sinusoidal obstruction syndrome. This is the first reported use in pediatrics of a condensed sequential immunotherapy/chemotherapy regimen in a pediatric leukemia patient.

A document by Irtiza Sheikh. Click on the document to view its contents.